you are in demo mode.    to view your own genetic profile, order your scan now.

Site search

  • your results
  • background
  • risk and prevention
  • scientific details
  • research
  • discussion
  • >>

Recent changes:
Jan 12 2010, 04:00 PM Added two risk variants for Europeans

Chronic Lymphocytic Leukemia

CLL is a cancer of the blood and bone marrow, characterized by the production of abnormal lymphocyte cells.

Please select a gender or population for your results.

This disease has different risk results depending on population or gender. Below you can select the ones you belong to.

Ethnicity:  European ancestry

Gender:   

Results can vary according to population and/or gender. Results currently based on:

European ancestry

Trait_world_map

Male

Trait_male_female

change


Cll
According to the selected literature, the relative genetic risk calculated from your genotype for males of European ancestry is 0.84. This corresponds to a 0.4% lifetime risk of developing chronic lymphocytic leukemia, which is 16% less than for males of European ancestry in general (source) . Note that these calculations may not include all risk factors.
The lifetime risk of your type
It is estimated that 42 of every 10000 males of European ancestry with your genotype variants develop this disease in their lifetime.
Cll
The average lifetime risk
On average, about 50 of every 10000 males of European ancestry develop this disease in their lifetime.
Cll

Consult with our experts

Need something clarified? If so, please feel free to contact our experts. Based on the nature of your questions, we may refer you to a genetic counselor.

ask a question about Chronic Lymphocytic Leukemia

Keep in mind

These are the results of calculations comparing your genetic sequence to sequence of participants in studies published in the world literature on genetic risk for this disease. Read more about how deCODEme calculates risks.

This test was developed and its performance characteristics determined by the deCODE genetics Diagnostic Laboratory. It has not been cleared or approved by the U. S. Food and Drug Administration (FDA).